Trial Profile
A Double-Blind, Randomized, Placebo-Controlled Factorial Study to Evaluate the Efficacy and Safety of TAK-475 [lapaquistat] and Simvastatin Alone and in Combination in Subjects With Hypercholesterolemia.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Lapaquistat (Primary) ; Simvastatin
- Indications Hypercholesterolaemia
- Focus Registrational; Therapeutic Use
- Sponsors Takeda
- 14 Jan 2010 Actual end date (May 2007) added as reported by ClinicalTrials.gov.
- 14 Jan 2009 Status changed from discontinued to completed, as reported by Clinicaltrials.gov.
- 28 Mar 2008 Status changed from in progress to discontinued. According to a Takeda media release, development of lapaquistat is being discontinued.